eCOA software for better clinical trials
eCOAs (electronic Clinical Outcome Assessments) and digital outcome measures delivered at industry-leading speed and quality to enhance your trial findings and fuel medical breakthroughs.
eCOA+ is part of Medable's unified data collection platform, which includes eConsent, telehealth, and sensors, with standardized integrations into your existing clinical ecosystem.
Medable eCOA+
Faster study build time
Pre-built and validated instruments
Available languages
Take eCOA off the critical path
Rapidly deploy quality studies and take eCOA off the critical path of study start-up with a reusable instrument library of 380+ standardized workflows and AI-enabled, purpose-built technology so you can work on what matters most, advancing patient care.
Unlock insights with real-time data capture
Capture objective and subjective participant data in a standardized and compliant manner. Medable’s eCOA+ combines eClinROs, ePROs, ePerfOs, eObsROs, and digital measures, so you can uncover clinically meaningful insights in real-time.
Engage patients with a better experience
Medable’s eCOA clinical trial solution improves inclusivity and accessibility, meeting the needs of patients in any geographic location and across diverse therapeutic areas, reducing burden and increasing retention.
The Medable difference
Reusable eCOA Library
Our library of 380+ reusable, pre-validated instruments, assessments and diaries ensure a standardized, consistent method of data collection that drives real-time decision making.
BYOD and provisioned devices
Accessible across web and/or mobile, provisioned devices or BYOD, unlocking patient populations that were previously out of reach while increasing patients' optionality.
Cross-platform TeleVisit
One seamless platform experience allows site and patient users to better engage and participate in a comfortable environment, reducing burden and increasing compliance.
Digital measures
Standardized integrations for sensors capturing digital physiological measures provide value across a variety of therapeutic areas including Oncology, Immunology, Cardiovascular, and more.
User friendy Platform
Consumer-grade UX, complete with notifications, reports, and submission-ready data, is vetted by our Patient Caregiver Network (PCN) and clinicians, ensuring accessibility.
24/7 Customer Support
Global customer care support throughout your trial for sites, patients and study teams. Our team ensure the best user experience to enable seamless technology adoption, protocol compliance, and overall user satisfaction.
Globally Compliant
Available in 70+ countries and 120+ locales, Medable’s platform adheres to standards set by the FDA, CFR21 Part 11, HIPAA, and GDPR.
Powered by AI
By harnessing intelligent automation, we can reduce delivery timelines by up to 50%, enabling an accelerated study start up to quickly capture novel endpoints.
A top 10 pharmaceutical company approached Medable seeking support for their Phase III diabetes study in the highly competitive weight loss market. Their primary goal was to reduce the client’s average study build timelines from 16-20 weeks, down to just 8 weeks, a reduction of more than 50%.See how Medable was able to meet the customer's goal with this case study.
eCOA+ Streamlined Evidence Generation
Frequently asked questions
eCOA stands for electronic clinical outcome assessment and uses electronic devices like tablets, desktop computers, and phones to collect data from trial participants. Participants complete diaries, questionnaires, or other prompts to communicate how they are feeling or functioning during the course of a clinical trial. eCOAs are part of the decentralized clinical trial (DCT) methodology and are essential to understanding whether a drug is reducing symptoms and improving patients’ quality of life.
Medable’s eCOA offering is part of our broader evidence generation offering: Patient-First Data Collection. Medable’s tools allow teams to build eCOA instruments (both validated instruments and eDiaries) that meet industry standards. Data collected from this system can be used for primary endpoints in pivotal studies. Study teams can store instruments, including translations, in a library for rapid deployment in future studies. Dashboards keep teams informed of all startup activities along the way. Teams may also access their library of prebuilt, validated instruments to improve study startup.
Yes. Medable's platform is multimodal, meaning patients can access our interface through the Patient app or a web browser. A BYOD model allows patients to use their own smartphone or other device for data capture during a site visit or remotely. Participants using devices they are already familiar with may lead to better compliance and ultimately, a better clinical trial experience. However, since some participants may be hesitant to download an app on their own device, or may not own a device that meets the requirements, it’s important to anticipate a percentage of provisioned devices, even in trials adopting a BYOD strategy.
The latest in eCOA
Case study: Medable reduces trial build from weeks to days
A top global clinical research organization (CRO) partnered with Medable to transform its approach to clinical trial building. Recognizing the inefficiencies in traditional build processes that often “take weeks,” the client leveraged Medable’s Studio platform with its latest AI capabilities to dramatically accelerate timelines, enhance transparency, and improve quality.
No more back and forth: Building eCOAs right the first time
Recently, Medable worked with a leading market research consultant to identify the pains and processes that sponsors and CROs encounter when building trials. Of the many that were presented, one issue kept reappearing, the back and forth processes for building COAs.
This feedback was instrumental in the development of Medable Studio, which was built to simplify the study build process, take eCOA off the critical path, and give sponsors and CROs total control over the trial build process.
Why ePROs in oncology are perfect for capturing the patient’s voice
Here are two statistics that may surprise you.
Number one, according to the WIRB-Copernicus Group, the number of oncology trials has skyrocketed over the last decade, almost doubling the number of all other therapeutic areas combined.
Number two, between 2010 and 2020, only 9 out of 108 FDA-approved oncology drugs, a mere 8.3%, included electronic patient-reported outcomes (ePROs) in their labeling.
Clearly, ePRO adoption is lagging in oncology trials. This comes despite recent guidance from the FDA (in 2021 and 2024) explaining how sponsors can use these technologies to ease trials for themselves and their patients.